First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <em>RET</em> Fusion-Positive NSCLC

CONCLUSIONS: Treatment with selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov number, …